Concepedia

Anastasios Stathis

AS

84

Publications

5.3K

Citations

34

H-Index

2006

Active since

Affiliations

Institute of Oncology Research(Current)

Università della Svizzera italiana

SIB Swiss Institute of Bioinformatics

Università degli Studi del Piemonte Orientale “Amedeo Avogadro”

Istituti di Ricovero e Cura a Carattere Scientifico

Anastasios Stathis is an author at Institute of Oncology Research specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

2006–2024

84

Publications

84

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 420 citations

, , +9

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 397 citations

, , +6

Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Anastasios Stathis, Emanuele Zucca, Mohamed Békradda et al. · Cancer Discovery · 2016 · 371 citations · Full text

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro et al. · Blood · 2018 · 326 citations · Full text

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Philippe L. Bédard, Josep Tabernero, Filip Jankú et al. · Clinical Cancer Research · 2014 · 318 citations · Full text

Rows per page

1–5 of 84